Editorial review: Medriva pages are written by named contributors, reviewed by clinical or subject-matter experts, and updated as evidence or regulatory status changes.

Semaglutide: Evidence, Side Effects, and Regulatory Status (2026)

Q: Is Semaglutide FDA approved?

FDA approved. See the regulatory status section above for details.

Q: Does Semaglutide work for weight loss?

Evidence is strong . See the linked use case hub for the full breakdown.

Q: How much does Semaglutide cost?

See the cost pages or the GLP 1 price/supply tracker where applicable.

Semaglutide is FDA-approved. Evidence grade: strong. This page is clinically reviewed.

TL;DR / Quick Facts

Semaglutide is Semaglutide is a long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and risk reduction in cardiovascular disease. The most commercially important peptide in 2026. FDA status: FDA-approved. Typical use cases: weight loss, longevity, mens health, womens health. Evidence grade: strong. Dosing is per the FDA label — set by your clinician. Common side effects: see below. Medriva editorial stance: follow the FDA label; do not use off-label without clinical supervision.

What it is

Semaglutide is a member of the GLP-1 receptor agonist class. Semaglutide mimics the incretin hormone GLP-1. It binds the GLP-1 receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central nervous system pathways.

What the evidence says

Evidence for Semaglutide is strong. Multiple phase 3 trials and post-market data support the labeled indications.

[Detailed evidence breakdown in the corresponding claim or pillar pages is linked at the bottom of this page.]

What it's used for

Commonly discussed uses of Semaglutide:

Weight Loss — strong evidence.
Additional uses listed in the linked use-case hubs; evidence varies by indication.

For the full list, see the linked use-case hubs below.

Typical dosing

Semaglutide dosing is determined by the approved label, indication, comorbidities, current medications, and clinician judgment. Medriva does not publish individualized dosing instructions or titration schedules. Review the current prescribing information and make changes only with a licensed clinician.

Side effects and risks

Common: Side effects vary by compound and indication; review the approved label or profile-specific safety data with a clinician.
Serious: Seek urgent care for severe allergic symptoms, chest pain, severe abdominal pain, persistent vomiting, or other severe reactions.
Long-term unknowns: For non-approved or research-use compounds, long-term human safety data may be limited.

Regulatory status

FDA-approved use(s): Ozempic (T2D, CV risk reduction); Wegovy (chronic weight management in adults with BMI ≥30, or ≥27 with comorbidity; adolescents ≥12); Rybelsus (oral T2D).
Compounded availability: see 503A vs 503B explainer
Research-use-only (RUO) availability: n/a
Banned in sport: see WADA & sports explainer

Cost and access

Semaglutide is available by prescription; see the cost page for the relevant indication. For pricing, see our cost pages or the GLP-1 price/supply tracker where applicable.

Who it might be appropriate for

Adults with a relevant diagnosed condition or clinical goal, under the supervision of a licensed clinician, who have no contraindications. Semaglutide is not for self-experimentation.

Who should not use it

Contraindications vary by compound, indication, pregnancy status, comorbidities, and current medications. For the full list, see the contraindications checklist and discuss with your clinician.

Medriva editorial stance

We describe the literature. We do not promote Semaglutide as a cure, treatment, or performance enhancer. We do not recommend it for self-experimentation. We do recommend that readers (a) understand the evidence grade (strong), (b) understand the regulatory status (FDA-approved), and (c) discuss with a licensed clinician before acting.

How to talk to a clinician

See our guide on how to talk to a clinician for a templated conversation.

Frequently Asked Questions

Is Semaglutide FDA-approved?

FDA-approved. See the regulatory status section above for details.

Does Semaglutide work for weight loss?

Evidence is strong. See the linked use-case hub for the full breakdown.

What are the side effects?

See the side effects section above. Discuss with your clinician.

How much does Semaglutide cost?

See the cost pages or the GLP-1 price/supply tracker where applicable.

Can I buy Semaglutide online?

By prescription only. Medriva does not sell peptides.

Author + Clinical reviewer

Author: Daniel Arora, MPH Clinical reviewer: Jonathan Reeves, MD Last reviewed: 2026-06-05

Next steps

Review the evidence grade and regulatory status before making decisions about Semaglutide.
Bring this page to a licensed clinician if you are discussing benefits, risks, or alternatives.
Subscribe to the Medriva Peptide Brief for evidence and regulatory updates.

Related use-case hubs

Related comparisons

Related guides

Editorial process

This page follows the Medriva Editorial Policy and the Clinical Review Methodology. Page last reviewed: 2026-06-05. Author: Daniel Arora, MPH. Clinical reviewer: Jonathan Reeves, MD.

Current source updates

For new regulator actions, compounding-policy changes, warning letters, shortage updates, and sports-rule changes, review the Peptide Tracker before relying on older summaries.